View Older Stories View More Recent Stories

Dec 17, 2025 04:12AM RBC Capital Reiterates Outperform Rating on Neurocrine Bio. (NBIX)
Dec 12, 2025 03:37AM Neurocrine Bio. (NBIX) PT Raised to $175 at Mizuho
Dec 10, 2025 09:16AM TD Cowen: 'Neurocrine Bio. (NBIX) Is a Top Biotech Pick'
Dec 8, 2025 05:18AM Neurocrine Bio. (NBIX) PT Raised to $180 at RBC Capital
Dec 5, 2025 05:29AM Neurocrine Bio. (NBIX) PT Raised to $200 at TD Cowen
Nov 28, 2025 07:01AM Canaccord Genuity Reiterates Buy Rating on Neurocrine Bio. (NBIX)
Nov 26, 2025 06:52AM Neurocrine Bio. (NBIX) Won't Have to Contract Aggressively in 2027 - Stifel
Nov 20, 2025 08:30AM Neurocrine study highlights differences between tardive dyskinesia drugs
Nov 16, 2025 03:00PM Where can biotech stocks go from here? RBC answers
Nov 3, 2025 09:08AM Neurocrine Bio. (NBIX) PT Raised to $147 at BMO Capital
Oct 29, 2025 11:07AM Neurocrine Bio. (NBIX) PT Raised to $172 at Truist Securities
Oct 29, 2025 10:12AM Neurocrine Bio. (NBIX) PT Raised to $183 at Stifel
Oct 29, 2025 07:28AM Neurocrine Bio. (NBIX) PT Raised to $184 at Needham
Oct 29, 2025 05:18AM Neurocrine Bio. (NBIX) PT Raised to $174 at Jefferies
Oct 29, 2025 04:46AM Neurocrine Bio. (NBIX) PT Raised to $189 at Goldman Sachs
Oct 28, 2025 04:02PM Neurocrine Biosciences (NBIX) Tops Q3 EPS by 58c
Oct 21, 2025 05:01AM Citi Starts Neurocrine Bio. (NBIX) at Buy
Oct 17, 2025 08:32AM Truist Securities: 'Is Biotech Back?!'
Oct 17, 2025 08:30AM Neurocrine shares data on INGREZZA 40 mg treatment for tardive dyskinesia
Oct 12, 2025 03:00PM Biotech stocks: Q3 earnings preview
Oct 9, 2025 09:38AM Neurocrine Bio. (NBIX) PT Raised to $195 at UBS
Oct 6, 2025 08:31AM Neurocrine shows 3-year safety data for Huntington's drug INGREZZA
Sep 23, 2025 08:30AM Neurocrine shows INGREZZA achieved tardive dyskinesia remission in 58% of patients
Sep 22, 2025 01:26PM Neurocrine Bio. (NBIX) PT Raised to $169 at Jefferies
Sep 22, 2025 09:44AM BMO Capital Reiterates Market Perform Rating on Neurocrine Bio. (NBIX), 'we await further derisking data'
Sep 22, 2025 07:39AM Stifel Reiterates Buy Rating on Neurocrine Bio. (NBIX)
Sep 22, 2025 04:47AM UBS Reiterates Buy Rating on Neurocrine Bio. (NBIX)
Sep 5, 2025 05:23AM Neurocrine Bio. (NBIX) PT Raised to $149 at RBC Capital
Jul 31, 2025 09:52AM Neurocrine Bio. (NBIX) PT Raised to $175 at Guggenheim
Jul 31, 2025 08:53AM Neurocrine Bio. (NBIX) PT Raised to $145 at Mizuho
Jul 31, 2025 06:57AM Neurocrine Bio. (NBIX) PT Raised to $124 at BMO Capital
Jul 30, 2025 04:13PM Neurocrine Biosciences (NBIX) Tops Q2 EPS by 69c ; Offers Guidance
Jul 23, 2025 07:16AM Cantor Fitzgerald Reiterates Overweight Rating on Neurocrine Bio. (NBIX)
Jul 21, 2025 07:32AM Truist Securities Starts Neurocrine Bio. (NBIX) at Buy
Jul 15, 2025 08:31AM Neurocrine shares registry data showing CAH treatment challenges
Jul 14, 2025 04:36PM Neurocrine presents one-year data showing weight improvements with CRENESSITY
Jul 14, 2025 08:31AM Neurocrine presents one-year CRENESSITY data at ENDO 2025 conference
Jul 10, 2025 02:26AM Goldman Sachs Starts Neurocrine Bio. (NBIX) at Buy
Jul 9, 2025 05:59AM Neurocrine Bio. (NBIX) PT Raised to $174 at UBS
Jul 7, 2025 07:04AM Neurocrine starts phase 1 trial for experimental CAH treatment
Jun 27, 2025 08:31AM Neurocrine Biosciences (NBIX) Presents New Post-Hoc Data Analyses from KINECT-HD Study
Jun 20, 2025 08:31AM Neurocrine Biosciences (NBIX) Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA Capsules in Older Adults with Tardive Dyskinesia
Jun 9, 2025 04:05PM Neurocrine Biosciences (NBIX) Appoints Lewis Choi as Chief Information Officer
Jun 4, 2025 06:16AM Guggenheim Reiterates Buy Rating on Neurocrine Bio. (NBIX)
Jun 2, 2025 06:58AM RBC Capital on Neurocrine Bio. (NBIX): 'We See Room for Additional Share Upside'
May 30, 2025 04:30PM Fate Therapeutics (FATE) names Matthew Abernethy to Board
May 28, 2025 04:07PM Neurocrine Biosciences (NBIX) Presents New Positive Data from Phase 2 Study of NBI-1117568
May 27, 2025 09:45AM Stifel Reiterates Buy Rating on Neurocrine Bio. (NBIX)
May 16, 2025 08:31AM Neurocrine Biosciences (NBIX) to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
May 16, 2025 08:26AM Neurocrine Biosciences (NBIX) Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia
View More Recent Stories View Older Stories